Daniel Bryan Goodman
banner
dbgoodman.bsky.social
Daniel Bryan Goodman
@dbgoodman.bsky.social
Assistant Professor at UPenn. Synthetic immunologist & computational biologist. Using DNA synth, multiplex assays and generative models to understand & engineer immune cell signaling & function. Church lab alum.
Web: www.dbgoodman.com
Why test #celltherapies one-by-one when you can use multiplexed #SynBio #proteinengineering & #ML to design, measure & track them at scale?

The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!

More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏
April 29, 2025 at 11:01 PM
Reposted by Daniel Bryan Goodman
AAV opens up the 80% of genome considered 'undruggable'. A key challenge and opportunity is to search that space for the right targets. Manufacturing capacity is sufficient to serve tens of millions of patients at safe doses, as long as we can find the right targets for efficacy.
March 20, 2025 at 2:29 PM
Reposted by Daniel Bryan Goodman
*dusting off hands* ah yes that should do it
March 18, 2025 at 5:26 AM
Reposted by Daniel Bryan Goodman
An SRO I have worked with on and off for 10+ yrs was fired. This person had almost 20 years of experience in their job and had cultivated an entire discipline by managing fair, through and rigorous reviews of grants across the entire field. How heartbreaking.
ATTENTION: TALENT AVAILABLE

It appears that termination of SROs from institute review branches at NIH is underway (or worse).

There are also program officers and SROs who have been terminated over the past month.

IF YOU HAVE POSITIONS FOR SKILLED SCIENTIST-ADMINISTRATORS, PLEASE POST INFO HERE
a red neon sign that says help wanted on a black background .
ALT: a red neon sign that says help wanted on a black background .
media.tenor.com
March 8, 2025 at 9:04 PM
Reposted by Daniel Bryan Goodman
On January 6th, 1995, my (now ex) wife and I boarded a flight from Heathrow to JFK on a one way ticket. We had two suitcases and about $900 in cash - this was everything we owned and we were moving to the US. We thought it was maybe for 2-3 years. I had visited the US once, for a conference, and
February 15, 2025 at 5:48 AM
Reposted by Daniel Bryan Goodman
I maxed out my credit card, emptied my savings account, and took out a loan to move from Alabama to Bethesda, MD. I don’t even qualify for unemployment since I’ve only worked at NIH for a month. I will be financially and medically devastated.

Seeking suggestions for anywhere that’s hiring!!
Today, along with 2,000 other NIH employees, I had to clear out my office 😭

It was truly the honor of my life to work with such incredibly passionate people focused on improving human health. I’ve never experienced a more positive culture where *everyone* cared about their job and serving others.
February 14, 2025 at 11:49 PM
Reposted by Daniel Bryan Goodman
When I was 12 my house exploded because of a propane gas leak. My single mom suffered a brain injury and became disabled. She couldn't hold a job. I caddied to help support the family. Food stamps helped us keep the fridge from being empty. So grateful for that support we had.
February 14, 2025 at 1:39 AM
Reposted by Daniel Bryan Goodman
Many people, including academics, don't understand what F&A is for. Please share to help.

1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)

2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...
February 10, 2025 at 4:39 PM
Reposted by Daniel Bryan Goodman
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.
February 8, 2025 at 9:21 PM
Reposted by Daniel Bryan Goodman
🎇🎄Some holiday reading: Overdue TWEETORIAL on the latest preprint from our lab 🎇🎄

In this work, superstar postdoc @xinhexue.bsky.social combined 2 kinds of pooled CRISPR screens to pinpoint noncoding regulatory elements and the transcription factors that activate these elements.
December 26, 2024 at 3:01 AM
Reposted by Daniel Bryan Goodman
Super excited to announce my new lab at the University of Michigan opening Jan 2025! 🎉We’ll study how cells work together to shape the GI tract, with ties to regeneration & disease.

Hiring at all levels—esp. a research tech to help launch the lab! Info: huyckelab.org

#DevBio #CellBio #Hiring
December 13, 2024 at 5:09 PM
Reposted by Daniel Bryan Goodman
A few more letters... and we can finally write amino acid sequence with protein structure encoded by amino acid sequence? 🧬🤔😀

@chrisfrank662.bsky.social , Dominik Schiwietz, Lara Fuss, Hendrik Dietz
www.biorxiv.org/content/10.1...
November 22, 2024 at 4:28 AM
Reposted by Daniel Bryan Goodman
Gentle reminder that retweets are important on BlueSky!
December 15, 2023 at 8:01 PM
Reposted by Daniel Bryan Goodman
#academicsky
For women and other underrepresented groups in AI:
Applications for the 2024 AI Residency has been extended to Dec 8th! Please apply www.deeplabcutairesidency.org
December 3, 2023 at 11:01 AM
Reposted by Daniel Bryan Goodman
Reposted by Daniel Bryan Goodman
Institute for Human Genetics (IHG) has multiple faculty positions open! We are looking for folks at any level, and across the range of the genetics/genomics spectrum! I chair the search for computational folks in stat or pop gen! Looking to welcome you!! aprecruit.ucsf.edu/JPF04729
October 6, 2023 at 4:39 AM
Reposted by Daniel Bryan Goodman
Excited to share our work on targeting Cas13 to splice junctions for isoform-specific RNA knockdown. We learned a lot about the experimental design, assessment and downstream analysis of this approach. Phenomenal effort from all involved! www.biorxiv.org/content/10.1...
Cas13d-mediated isoform-specific RNA knockdown with a unified computational and experimental toolbox
bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
www.biorxiv.org
September 14, 2023 at 2:44 PM
Reposted by Daniel Bryan Goodman
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

How does anti-PD-1 therapy work? Via reinvigoration of cytotoxicity among PD/1+CD8+ T cells it seems.

https://www.science.org/doi/10.1126/sciimmunol.adf49
68
September 13, 2023 at 10:59 AM